The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy

Journal of Nuclear Medicine

Volumn 51, Issue 6, 2010, Pages 875-882

  Srirajaskanthan, Rajaventhan ^a   Kayani, Irfan ^b   Quigley, Anne Marie ^a   Soh, Jade ^a   Caplin, Martyn E ^a   Bomanji, Jamshed ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

111In DTPA octreotide scintigraphy; 68Ga DOTATATE PET; Neuroendocrine tumor; Peptide receptor therapy; Somatostatin analogs

Indexed keywords

COVIDIEN; DOTATATE GA 68; GADOTERATE MEGLUMINE; IOHEXOL; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 68GA DOTATATE; 68GA-DOTATATE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; OCTREOTIDE; ORGANOMETALLIC COMPOUND; PENTETIC ACID; SDZ 215 811; SDZ 215-811; SOMATOSTATIN RECEPTOR;

ABDOMINAL CANCER; ADULT; AGED; ARTICLE; BONE CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CROSS-SECTIONAL STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; HISTOLOGY; HUMAN; INTERMETHOD COMPARISON; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MESENTERY TUMOR; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PANCREAS CANCER; PELVIS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPLEEN CANCER; TUMOR VOLUME; ADOLESCENT; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PENTETIC ACID; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, SOMATOSTATIN; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 77953928471     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.066134     Document Type: Article

References (26)

1. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumour. Lancet. 1998;352:799-805.
2. Pelosi G, Volante M, Papotti M, Sonzogni A, Masullo M, Viale G. Peptide receptors in neuroendocrine tumors of the lung as potential tools for radionuclide diagnosis and therapy. Q J Nucl Med Mol Imaging. 2006;50:272-287.
3. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427.
4. Reubi JC. Somatostatin receptors as markers for endocrine tumors [abstract]. JAMA. 1987;257(suppl):3277.
5. Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors: a correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. 2002;440:461-475.
6. Lamberts SW, Reubi JC, Krenning EP. Somatostatin and the concept of peptide receptor scintigraphy in oncology. Semin Oncol. 1994;21(suppl 13):1-5.
7. 123I-Tyr3]- octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
8. 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med. 1999;40:762-767.
9. 111In] DTPA-octreotide scintigraphy (OctreoScan): a comparative study with CT and MR imaging. QJM. 1998;91:295-301.
10. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228-247.
11. 111In pentetreotide in the PET era. Q J Nucl Med Mol Imaging. 2005;49:225-235.
12. Al-Nahhas A, Win Z, Szyszko T, Singh A, Khan S, Rubello D. What can gallium-68 PET add to receptor and molecular imaging? Eur J Nucl Med Mol Imaging. 2007;34:1897-1901. (Pubitemid 350212142)
13. 111In-DTPAOC (OctreoScan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617-1626.
14. 68Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518.
15. 68Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751-1757.
16. 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006;33:1115-1122.
17. 18F-FDG. Cancer. 2008;112:2447-2455.
18. 177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754-2762.
19. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395-401.
20. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451:757-762.
21. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-282.
22. 111In-pentetreotide. J Nucl Med. 2001;42:1134-1138.
23. 111In]-DTPAOC SPECT: first results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003;5:42-48.
24. Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferonalpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005;3:761-771.
25. Srirajaskanthan R, Watkins J, Marelli L, Khan K, Caplin ME. Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies. Neuroendocrinology. 2009;89:308-314.
26. 11C-5-hydroxytryptophan positron emission tomography. J Clin Oncol. 2008;26:1489-1495.